Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 2/20 | 0.69 |
| ▸ | PNP | P00491 | 7/20 | 0.65 |
| ▸ | HPRT1 | P00492 | 6/20 | 0.63 |
| ▸ | USP2 | O75604 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | EDNRA | P25101 | 1/20 | 0.60 |
| ▸ | HTR2A | P28223 | 1/20 | 0.60 |
| ▸ | RECQL | P46063 | 1/20 | 0.60 |
| ▸ | BLM | P54132 | 1/20 | 0.60 |
| ▸ | HBB | P68871 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3793003 | 0.93 | TK1 (0.76) | TK1PNPHPRT1 | |
| SCHEMBL29286376 | 0.91 | TK1 (0.76) | TK1PNPHPRT1USP2TSHR | |
| SCHEMBL9806969 | 0.87 | TK1 (0.71) | TK1PNPHPRT1USP2TSHR | |
| SCHEMBL28223283 | 0.85 | TK1 (0.69) | TK1PNPHPRT1USP2TSHR | |
| SCHEMBL667796 | 0.85 | TK1 (0.69) | TK1PNPHPRT1USP2TSHR | |
| SCHEMBL350397 | 0.85 | TK1 (0.82) | TK1PNPHPRT1USP2TSHR | |
| SCHEMBL9960816 | 0.84 | PNP (0.68) | TK1PNPHPRT1USP2TSHR | |
| SCHEMBL15743134 | 0.84 | TK1 (0.76) | TK1PNPHPRT1USP2TSHR | |
| SCHEMBL18521979 | 0.83 | PNP (0.66) | TK1PNPHPRT1USP2TSHR | |
| SCHEMBL3836263 | 0.83 | TK1 (0.92) | TK1PNPHPRT1USP2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230045112-A1 | DISULFIRAM AND OTHER REDOX-RELATED COMPOSITIONS FOR BRAIN TUMORS | TEXAS TECH UNIVERSITY SYSTEM | 2023-02-09 | — | — | US | disclosed |
| US-20200109362-A1 | METHODS FOR CELL PROLIFERATION AND TOXICITY TESTING | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2020-04-09 | — | — | US | disclosed |
| CN-107903267-B | Azo aromatic nitrogen mustard-chloroethyl nitrosourea coupled compound, preparation method and application | 北京工业大学 | 2020-02-21 | — | — | CN | disclosed |
| CN-108484604-B | Azo aromatic nitrogen oxide-chloroethyl nitrosourea coupling molecule targeting tumor hypoxia, and preparation method and application thereof | 北京工业大学 | 2020-01-17 | — | — | CN | disclosed |
| US-20180147178-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS INCLUDING SUBSTITUTED HEXITOLS SUCH AS DIANHYDROGALACTITOL AND DIACETYLDIANHYDROGALACTITOL | DELMAR PHARMACEUTICALS INC (CA) | 2018-05-31 | — | — | US | disclosed |
| CN-107903267-A | A kind of compound and preparation method and application of the coupling of azo aryl nitrogen mustard chlorethylnitrosourea | 北京工业大学 | 2018-04-13 | — | — | CN | disclosed |
| US-9901563-B2 | Compositions to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dianhydrogalactitol and diacetyldianhydrogalactitol | DELMAR PHARMACEUTICALS, INC. (CA) | 2018-02-27 | — | — | US | disclosed |
| CN-107722010-A | A kind of hypoxemia activation chlorethylnitrosourea containing nitroimidazole group and its preparation method and application | 北京工业大学 | 2018-02-23 | — | — | CN | disclosed |
| WO-2017223254-A1 | METHODS FOR CELL PROLIFERATION AND TOXICITY TESTING | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2017-12-28 | — | — | WO | disclosed |
| CN-105503874-B | Hypoxemia activates joint chloroethylnitrosoureas compound and preparation method and application | 北京工业大学 | 2017-10-27 | — | — | CN | disclosed |
| EP-0702683-B1 | 06-SUBSTITUTED GUANINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND THEIR USE IN TREATING TUMOUR CELLS | CANCER REC TECH LTD (GB) | 2003-09-17 | — | — | EP | disclosed |
| EP-0910246-A4 | USE OF MUTANT ALKYLTRANSFERASES FOR GENE THERAPY TO PROTECT FROM TOXICITY OF THERAPEUTIC ALKYLATING AGENTS | PENN STATE RES FOUND (US) | 2003-07-02 | — | — | EP | disclosed |
| US-20020198264-A1 | Methoxyamine combinations in the treatment of cancer | CASE WESTERN RESERVE UNIVERSITY (US) | 2002-12-26 | — | — | US | disclosed |
| US-6465448-B1 | TREATING TUMORS RESISTANT TO TEMOZOLOMIDE ALONE | CASE WESTERN RESERVE UNIVERSITY | 2002-10-15 | — | — | US | disclosed |
| WO-2001012199-A2 | METHOXYAMINE POTENTIATION OF TEMOZOLOMIDE ANTI-CANCER ACTIVITY | CASE WESTERN RESERVE UNIVERSITY (US) | 2001-02-22 | — | — | WO | disclosed |
| WO-1999025386-A1 | delta-O6-METHYLGUANINE-DNA METHYLTRANSFERASE GENE TRANSFER FOR O6-BENZYLGUANINE AND (N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA) RESISTANCE | CASE WESTERN RESERVE UNIVERSITY (US) | 1999-05-27 | — | — | WO | disclosed |
| EP-0910246-A1 | USE OF MUTANT ALKYLTRANSFERASES FOR GENE THERAPY TO PROTECT FROM TOXICITY OF THERAPEUTIC ALKYLATING AGENTS | THE PENN STATE RESEARCH FOUNDATION (US) | 1999-04-28 | — | — | EP | disclosed |
| WO-1997035477-A1 | USE OF MUTANT ALKYLTRANSFERASES FOR GENE THERAPY TO PROTECT FROM TOXICITY OF THERAPEUTIC ALKYLATING AGENTS | THE PENN STATE RESEARCH FOUNDATION (US) | 1997-10-02 | — | — | WO | disclosed |
| EP-0702683-A1 | 06-SUBSTITUTED GUANINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND THEIR USE IN TREATING TUMOUR CELLS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1996-03-27 | — | — | EP | disclosed |
| WO-1994029312-A1 | O6-SUBSTITUTED GUANINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND THEIR USE IN TREATING TUMOUR CELLS | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1994-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230045112-A1 | DISULFIRAM AND OTHER REDOX-RELATED COMPOSITIONS FOR BRAIN TUMORS | MGMT, SHMT2, SHMT1 | TK1 504/4885PNP 1267/4885HPRT1 410/4885 |
| US-20180147178-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS INCLUDING SUBSTITUTED HEXITOLS SUCH AS DIANHYDROGALACTITOL AND DIACETYLDIANHYDROGALACTITOL | DDOST, DAD1, B3GAT3 | TK1 1394/4885PNP 1702/4885HPRT1 556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.